Abstract
The National Center for Tumor Diseases (NCT) in Heidelberg has implemented a highly innovative Precision Oncology Program (NCT POP) as a center-wide master strategy. It coordinates all translational activities and focuses resources towards individualized cancer medicine, including patient-oriented strategies in genomics, proteomics, immunology, radiooncology, prevention, and early clinical development. To achieve clinical implementation, NCT POP employs a center-wide umbrella protocol that provides all components of a clinical implementation workflow for high-throughput molecular diagnostics. Thus, it is possible to perform and evaluate molecular diagnostics on materials from all consenting NCT patients, with the explicit purpose of stratifying each patient for the best treatment or trial strategy. In order to best integrate and exploit the data produced in all NCT programs, a central NCT DataThereHouse contains a working copy of every patient-related dataset from all IT sources to enable efficient retrieval, aggregation, and evaluation of molecular and clinical data for clinical decision making and translational research. NCT’s overall aim is to provide optimal individualization of treatment decisions according to the specific needs of each individual patient by reaching across traditional disciplines and academic departments.
Kurz-CV
Prof. Christof von Kalle has been Director of the Department of Translational Oncology at NCT and at DKFZ since July 2005, and chairs the NCT Board of Directors. He coordinates overall NCT activities with the primary goal of facilitating excellence in translational and clinical research at DKFZ and the Heidelberg University Hospital. As physician scientist with a clinical background in hematology/oncology, he is an internationally renowned leader in stem cell research, mutation analysis, and gene transfer. Prof. Christof von Kalle has a scientific background in treatment of rare genetic diseases, performs research on gene therapy induced for mutations in humans, and aims at treating cancer as multiple molecular diseases in one cell.
Hosts
Prof. Dr. Christoph Meinel, Dr. Matthieu-P. Schapranow
